Prospective, multicenter, open-label study to evaluate the efficacy of esmolol in the early identification of cardiovascular disorders induced by cirrhosis, diabetes mellitus and cardiotoxic treatments (bB-ECHO).
To study the efficacy of esmolol in the early identification of cardiovascular alterations induced by cirrhosis, diabetes mellitus, and cardiotoxic treatments.
Esmolol is a drug used in routine medical practice for the treatment of cardiac arrhythmias or in serious situations where it is necessary to rapidly control arterial hypertension.
- Reference: bB-ECHO
- Start date: 1 de january de 2021
- End date: 31 de december de 2024
- Funded by: Carlos III Health Institute
- Type: Nacional
Need more information?
If you are interested in learning more about our research, please contact us.